These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21979826)

  • 21. Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis.
    Seriolo B; Paolino S; Ferrone C; Cutolo M
    Clin Rheumatol; 2007 Oct; 26(10):1799-800. PubMed ID: 17646897
    [No Abstract]   [Full Text] [Related]  

  • 22. [Biological agents for therapy of rheumatoid arthritis--overview].
    Takeuchi T
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():513-6. PubMed ID: 15799409
    [No Abstract]   [Full Text] [Related]  

  • 23. A comparison of safety profiles of tumour necrosis factor α inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C.
    Chen YM; Chen HH; Chen YH; Hsieh TY; Hsieh CW; Hung WT; Lan JL; Chen DY
    Ann Rheum Dis; 2015 Mar; 74(3):626-7. PubMed ID: 25452310
    [No Abstract]   [Full Text] [Related]  

  • 24. [TNF antagonists in therapy of rheumatoid arthritis].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 1999 Nov; 22(11):334-9. PubMed ID: 10596266
    [No Abstract]   [Full Text] [Related]  

  • 25. The yin and yang of tumor necrosis factor inhibitors.
    Calabrese L
    Cleve Clin J Med; 2006 Mar; 73(3):251-6. PubMed ID: 16548447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Henoch Schönlein purpura following etanercept treatment of rheumatoid arthritis.
    Duffy TN; Genta M; Moll S; Martin PY; Gabay C
    Clin Exp Rheumatol; 2006; 24(2 Suppl 41):S106. PubMed ID: 16859610
    [No Abstract]   [Full Text] [Related]  

  • 27. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

  • 28. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA; Agudo M
    Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
    [No Abstract]   [Full Text] [Related]  

  • 29. Anti-TNF-alpha therapies: they are all the same (aren't they?).
    Mpofu S; Fatima F; Moots RJ
    Rheumatology (Oxford); 2005 Mar; 44(3):271-3. PubMed ID: 15561736
    [No Abstract]   [Full Text] [Related]  

  • 30. Maintaining and optimising anti-TNF therapy.
    Somerville M
    Musculoskeletal Care; 2007 Dec; 5 Suppl 1():1-17. PubMed ID: 18050263
    [No Abstract]   [Full Text] [Related]  

  • 31. TNFalpha antagonists in rheumatoid arthritis patients seen in everyday practice.
    Falgarone G; Duclos M; Boissier MC
    Joint Bone Spine; 2007 Dec; 74(6):523-6. PubMed ID: 18092377
    [No Abstract]   [Full Text] [Related]  

  • 32. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.
    van der Stoep D; Braunstahl GJ; van Zeben J; Wouters J
    J Rheumatol; 2009 Dec; 36(12):2847-8. PubMed ID: 19966199
    [No Abstract]   [Full Text] [Related]  

  • 33. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
    Kastbom A; Bratt J; Ernestam S; Lampa J; Padyukov L; Söderkvist P; Skogh T
    Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New drugs for rheumatoid arthritis.
    Olsen NJ; Stein CM
    N Engl J Med; 2004 May; 350(21):2167-79. PubMed ID: 15152062
    [No Abstract]   [Full Text] [Related]  

  • 35. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis?
    Gabriel SE
    Arthritis Rheum; 2008 Mar; 58(3):637-40. PubMed ID: 18311805
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of rheumatoid arthritis with etanercept.
    Genovese MC; Kremer JM
    Rheum Dis Clin North Am; 2004 May; 30(2):311-28, vi-vii. PubMed ID: 15172043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials.
    Pincus T; Yazici Y; van Vollenhoven R
    J Rheumatol; 2006 Dec; 33(12):2372-5. PubMed ID: 17143975
    [No Abstract]   [Full Text] [Related]  

  • 38. COMET's path, and the new biologicals in rheumatoid arthritis.
    Kremer JM
    Lancet; 2008 Aug; 372(9636):347-8. PubMed ID: 18635257
    [No Abstract]   [Full Text] [Related]  

  • 39. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
    Lourari S; Prey S; Livideanu C; Jamard B; Lamant L; Cantagrel A; Paul C
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):967-8. PubMed ID: 19192017
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.